Pharmadule Morimatsu, a subsidiary of Morimatsu International Holdings, and WuXi Biologics have officially entered into a global strategic cooperation for the Singapore CRDMO (Contract research developmnent and manufacturing organisation) Centre project of China-based WuXi Biologics.

As leaders in their respective fields, this strategic partnership marks an important milestone in both companies' business growth and development. Also, it's a strategic move in enabling their customers across the world. Moving forward, WuXi Biologics and Pharmadule Morimatsu will continue to explore further cooperation and seek more collaborations opportunities on a global basis.

This strategic cooperation starts with the integrated modular plant of two important production facilities in the Singapore CRDMO Centre of WuXi Biologics, and will include design, manufacturing, FAT, installation, commissioning and validation.

The project will adopt a new generation of modular fabrication, and the majority of works will be built, assembled and FAT-tested in Morimatsu's workshop. The quality, schedule, cost and risk of the project will be well managed and controlled. Compared with conventional construction, this method also greatly shortens the project cycle.